{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-005871","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.961975+00:00","generated_at":"2026-06-05T08:58:50.880878+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monopar receives additional 180-day Nasdaq extension to Aug 26, 2024 to meet $1 bid price rule","bullets":["Nasdaq granted Monopar extension to August 26, 2024 to regain compliance with $1.00 minimum bid price requirement.","Original 180-day period ended Feb 26, 2024; company failed to meet $1.00 closing bid for 10 consecutive days.","Company may consider reverse stock split if approved by shareholders to regain compliance.","No assurance of compliance; failure could lead to delisting and potential appeal."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-005871","json":"https://secwatch.observer/filing/0001437749-24-005871.json","markdown":"https://secwatch.observer/filing/0001437749-24-005871.md","text":"https://secwatch.observer/filing/0001437749-24-005871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924005871/0001437749-24-005871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924005871/mnpr20240228_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:58:50.880878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ad3857cd1d0756cb73777aa2cd30bd4f92dbd1d","claim":"Monopar Therapeutics received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"February 27, 2024, the Company received a letter from Nasdaq notifying that the Company had been granted an additional 180-day extension to August 26, 2024 (“Extended Compliance Period”) to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time during the Extended Compliance Period, the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of 10 consecutive business days or up to 20 business days in certain circumstances in NASDAQ's discretion, the Staff will provide written confirmation","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924005871/0001437749-24-005871-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}